Avanos Medical, Inc.
AVNS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.98 | 0.00 | -0.25 | 0.00 |
| FCF Yield | 1.31% | -0.74% | 2.88% | 7.25% |
| EV / EBITDA | 59.96 | -9.57 | 32.92 | -1.95 |
| Quality | ||||
| ROIC | 0.01% | 0.80% | 0.50% | 1.16% |
| Gross Margin | 48.37% | 52.63% | 53.61% | 55.29% |
| Cash Conversion Ratio | -10.00 | -0.09 | 3.89 | -0.15 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.89% | 0.48% | 0.25% | -1.61% |
| Free Cash Flow Growth | 266.67% | -122.11% | -64.22% | 165.50% |
| Safety | ||||
| Net Debt / EBITDA | 6.32 | -0.74 | 2.05 | -0.15 |
| Interest Coverage | 0.06 | 3.65 | 3.48 | 4.46 |
| Efficiency | ||||
| Inventory Turnover | 0.61 | 0.58 | 0.56 | 0.58 |
| Cash Conversion Cycle | 150.95 | 158.62 | 162.99 | 161.26 |